abstract |
Disclosed is: an antibody directed against FGF23; and a pharmaceutical co mposition (e.g., a prophylactic or therapeutic agent) for a disease which ca n be prevented or treated by inhibiting the activity of FGF23 by using the a ntibody. Specifically disclosed is an antibody directed against human FGF23 which is produced by hybridoma C10 (Accession Number: FERM BP-10772) or a fu nctional fragment of the antibody. |